key: cord-0838883-sj897bo9 authors: Hatmal, Ma'mon M.; Abuyman, Omar; Taha, Mutasem title: Docking-Generated Multiple Ligand Poses for Bootstrapping Bioactivity Classifying Machine Learning: Repurposing Covalent Inhibitors for COVID-19-Related TMPRSS2 as Case Study date: 2021-08-19 journal: Comput Struct Biotechnol J DOI: 10.1016/j.csbj.2021.08.023 sha: bb8675145db9870ce92b3ceecdbb40c37d26871d doc_id: 838883 cord_uid: sj897bo9 In the present work we introduce the use of multiple docked poses for bootstrapping machine learning-based QSAR modelling. Ligand-receptor contact fingerprints are implemented as descriptor variables. We implemented this method for the discovery of potential inhibitors of the serine protease enzyme TMPRSS2 involved the infectivity of coronaviruses. Several machine learners were scanned, however, Xgboost, support vector machines (SVM) and random forests (RF) were the best with testing set accuracies reaching 90%. Three potential hits were identified upon using the method to scan known untested FDA approved drugs against TMPRSS2. Subsequent molecular dynamics simulation and covalent docking supported the results of the new computational approach. 1 Introduction 2 Docking algorithms explore the conformational space of bound ligand(s) by sampling 3 numerous ligand conformations/poses within the targeted binding site. The binding 4 enthalpy of each docked pose/conformation is evaluated employing force fields that 5 calculate interactions between ligand-protein complementary groups (1) (2) (3) (4) . However, 6 docking engines ignore entropic contributions in binding and therefore need to be 7 guided by scoring functions to select realistic docked poses . Modern docking 8 methods can reproduce an experimental ligand crystallographic pose within high- 9 ranking solutions. However, scoring functions are usually unable to evaluate binding 10 free energies to accurately rank docked poses (1, 3, (34) (35) (36) (37) . 11 The concept of Ligand-Receptor Contacts Fingerprints (LRCFs) is well established 12 (38). It proceeds by either mapping out all binding site atoms that contact a list of 13 docked potent ligands and evade inactive compounds (38-41), or identify binding site 14 atoms that frequently contact a particular bound ligand during molecular dynamics or 15 related simulations (42-44). Significant binding site contacts can be transformed into 16 pharmacophores (38-44). A related concept to LRCFs is the interaction fingerprints 17 (IFPs) (45-51), which were used as postdock equivalents to scoring functions (45, 46, 18 52) or as means for virtual screening by similarity search (46, 49, 53, 54) . 19 Machine learning (ML) in drug discovery involves the implementation of statistical 20 means for learning and predicting molecular properties (55-62). The following are 21 popular ML algorithms used in computer-aided drug design and discovery and were 22 evaluated in the current research: Random Forest (RF) (61, 63); Naïve Bayesian (NB) 23 (64-68); eXtreme Gradient Boosting (XGBoost) (69, 70); K-nearest neighbors (kNN) 24 (71); Support vector machine (SVM) (72,73); probabilistic neural networks (PNN) (74-1 79); and multilayer perceptron (MLP) (80,81). However, ML needs to be validated vis-2 à-vis statistical accuracy. Bootstrapping (BS) is a commonly used statistical approach to 3 assign accuracy values for ML models. BS is a resampling method that uses random 4 sampling with replacement to assign accuracy measurements to sample estimates 5 particularly in situations of limited training data (82-84). 6 We herein propose to use multiple docked poses (up to hundreds per ligand), generated 7 by a number of docking engines/scoring functions for a list of active and inactive 8 ligands, to bootstrap bioactivity ML classifiers using LRCFs descriptors. The rational is 9 based on a plausible assumption: Since docking algorithms implement reasonable 10 enthalpy estimating methods, then all docked conformers/poses are enthalpically 11 plausible, particularly for potent ligands. Therefore, ML-based convergence, among 12 numerous docked poses/conformers of potent ligands, on certain group of atom contacts 13 within the binding site highlights the significance of those contacts and their collective 14 ability to classify docked virtual screening hits, i.e., as active or inactive. This method is 15 reminiscent of 4D-QSAR, which uses molecular dynamics simulations to create 16 conformation-dependent molecular descriptors (179). Still, our approach is less 17 computationally extensive and more suited for virtual screening purposes. 18 We applied this innovative concept, i.e., bootstrapping ML with multiple docked poses, 19 to virtually screen and repurpose known drug molecules against the COVID-19-related 20 enzyme transmembrane serine protease 2 (TMPRSS2). 21 TMPRSS2 is a cell surface serine protease involved in priming entry proteins necessary 22 for respiratory viruses, e.g., influenza and COVID19, to cross cellular membranes (85- i.e., against TMPRSS2, of reversible and irreversible binding capacity. Reversible and 2 irreversible active inhibitors are rather easy to define. However, inactive reversible and 3 irreversible inhibitors warrant more explanation: These are molecules with or without 4 covalent warheads, respectively, which were explicitly reported as being inactive 5 against TMPRSS2. 6 The collected compounds were ionized, tautomerized and docked/scored into 7 TMPRSS2. Identical or closely similar docked poses were filtered out using proper 8 RMSD filter. Reasonable docked poses (as judged by plausible consensus among 9 docking engines and scoring functions) were split into training and testing sets for ML. 10 Several ML methods were evaluated and the best were used to predict the TMPRSS2 11 bioactivity classification of docked poses of FDA-approved drugs. Promising hits were 12 further evaluated by covalent docking and molecular dynamics simulations. Three hits 13 were found to be potential potent inhibitors of TMPRSS2, namely, capreomycin, 14 aspoxicillin and fosamprenavir. carbamates, 23 β-lactams and 9 aromatic esters). 21 However, to reduce the number of modeled compounds, it was decided to use principal This shortlisted the modelled compounds into 107 divided into 15 "actives" (of which 2 two are irreversible and 13 reversible inhibitors) and 92 "inactives" (of which 12 have 3 nitro warheads, 9 with nitrile warheads, 6 Michael acceptors, 18 carbamates, 16 β-4 lactams, 2 aromatic esters, one α-keto-amide and 26 compounds lacking any reactive 5 warheads). Table 2 shows the chemical structures of the modeled compounds and their 6 reported bioactivities (if available) (90, 97, 137, 140). 7 Prior to docking, the modelled compounds were appropriately ionized using the Prepare 8 Ligands protocol in Discovery Studio (version 4.5) assuming pH range of 6.5-8.5. Additionally, the same protocol was also used to generate tautomeric forms of each 10 compound. This yielded 338 tautomeric forms (30 for the "active" inhibitors and 308 11 for the "inactive" members) for subsequent docking studies. Coordinates which are conserved between the target and the template are copied from 16 The ligand present in the template structure (5ce1) was transferred by homology to the The global and per-residue model quality has been assessed using tools implemented in The collected set of inhibitors (1-107, Table 1 ) were docked into the homology model Energy were calculated using Momany-Rone ligand partial charge method. 3 It was decided to select docked conformers/poses based on consensus among the 9 4 scoring functions (154, 155). The consensus function assigned a value of 1 for any 5 molecular pose ranked within the highest 20% by the particular scoring function; 6 otherwise, it was assigned a zero value (i.e., fit was within the lowest 80%). corresponds to different binding site atom. The matrix is filled with binary code, 5 whereby "zeros" correspond to inter-atomic distances >2.5 Å and "ones" for distances 6 binding site atoms at distances ≤ 2.5 Å. Naïve Bayesian (NB) 21 NB is a simple classifier whereby class labels are predicted and assigned to external 22 observations based on vectors of descriptors for some finite set of training observations. NB classifier assumes each descriptor to contribute independently to the probability that 24 certain observation (e.g., compound) belongs to a particular class (e.g., active or implemented in KNIME). Table 2 ). 14 Accuracy = TP + TN …………(1) 15 where, TP is the true positive (correctly classified actives), TN true negatives (truly 16 classified inactives), and n is the total number of evaluated compounds. where P o is the relative observed agreement among raters (i.e., accuracy), and P e is the 19 hypothetical probability of chance agreement. This is done by using the observed data 20 to calculate the probabilities of each observer randomly seeing each category. If the Step size was set to be 2 9 femto-seconds (fs). During the heating phase, the temperature of the system was raised 16 17 Covalent Docking 18 19 Capreomycin and aspoxicillin were covalently docked into TMPRSS2 homology model 9 Homology modeling of TMPRSS2 11 Since TMPRSS2 had no known crystallographic structure at the time of preparing this 12 manuscript, it was necessary to build an appropriate homology model for this target. 13 Sequence data for TMPRSS2 was obtained from Pubmed (GenBank accession number 14 NP_001128571 conserved. Figure 3A compares TMPRSS2 sequence to the template protein Hepsin. 9 The resulting homology structure was evaluated employing structure assessment tools Data collection, Docking, Scoring and Machine Learning. 2 The literature was carefully searched for TMRPSS2 inhibitors. The search identified 3 1064 inhibitors that can be unequivocally classified as "active" (IC 50 ≤ 1,000 nM) or 4 "inactive" (IC 50 ≥ 10,000 nM) as in the Data Collection section under Experimental. 5 However, we opted to select a subset of inhibitors for performing this study partially to 6 minimize the computational cost, but mainly, to assess the possibility of exploiting The modeled compounds were appropriately ionized and tautomerized yielding 338 22 tautomeric forms ready for docking. The structures were then docked into the binding pocket of TMPPRSS2 homology to compare whole docked nafamostat with partial crystallographic fragment in 7meq. 10 As an alternative we opted to gauge the success of the docking-scoring settings by 11 measuring the distance separating the warhead of docked nafamostat poses from the 12 hydroxyl of Ser478 (as in Figure 5B ). Interestingly, 4 out of 285 docked poses were These results further support the notion that the implemented docking/scoring 24 conditions segregate active compounds from inactives by allocating them distinct 25 binding poses and regions within the binding site. 1 We hypothesize that convergence of particularly high-quality docked poses, 2 corresponding to active ligands, on certain unique binding site contacts (i.e., not 3 contacted by high quality docked poses of inactive ligands) highlights the significance 4 of those binding site points as activity discriminators. Figure 6 illustrates this point: 5 Clearly, the optimal docked pose of active inhibitor 12 (table 2) The apparent imbalance between poses corresponding to active and inactive ligands is To further exclude the possibility of chance correlation we performed y-scrambling 6 validation experiment. In this test, 100 random bioactivity data are generated. 7 Subsequently, each learner is challenged to use these random data to generate ML 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 asterisks in table 2) . c Re-substitution: Accuracy and Cohen's Kappa determined by applying the particular ML model to predict the same training compounds used to build the model. d Performed using optimized nu value of 0.1. e Performed using optimized k value of 6 (number of neighbors). e Performed using 3 hidden layers, 100 neuron per layer, and 100 iterations (epochs). g RF ML models were validated by Out-of-Bag validation instead of Leave 20% out cross-validation for accuracy and Cohen's Kappa. 3 To utilize optimal ML models to search for potential anti-TMPRSS2 inhibitors within 4 FDA-approved drugs, it was decided to screen 155 drug molecules of reactive warheads 5 (supplementary table SM-2). All screened molecules were not tested before against 6 TMPRSS2. Virtual screening commenced by properly ionizing and tautomerizing screened 8 molecules. Subsequently, they were docked, scored and RMSD-filtered utilizing the 9 same settings implemented for the training and testing sets. The resulting docked poses 10 were then used to generate corresponding LRCFs in exactly the same manner as in the 11 training and testing sets. Subsequently, the resulting LRCFs were substituted in the best 12 ML models, namely, Xgboost, nu-SVM and RF, to predict the activity label of each 13 docked pose/conformer. This resulted in a situation where each screened compound 14 yielded a set of poses that are assigned either "active" or "inactive" labels. This 15 prompted us to define a threshold by which to consider certain screened molecule as 16 being promising or not, i.e., as anti-TMPRSS2, based on the ratio of docked 17 poses/conformers predicted to be "active" compared to those predicted to be "inactive". 18 We decided that the most reasonable way to define such a threshold is to evaluate the 19 active/inactive ratios within the testing set. It can be reasonably assumed the least 20 active-to-inactive ratio of unequivocally documented active inhibitor represents an 21 acceptable threshold for identifying potentially new active hits. Table 4 shows the 22 percentages of active poses of testing compounds as predicted by the top three ML (i.e., 23 Xgboost, nu-SVM and RF). 24 Clearly from table 4, the anti-TMPRSS2 inhibitor 2 (camostate, Ki = 1000nM, Table 2 ) 25 shows the smallest ratios of predicted active-to-inactive docked poses among other 26 inhibitors in the testing set, and therefore, it can be used to discriminate actives among Table 5 shows the predicted active-to-inactive ratios of the screened compounds. 10 Clearly all three top MLs agreed on three drugs to exhibit active-to-inactive ratios 11 exceeding the corresponding thresholds of camostat in table 4. The three compounds Table 5 : Screened drug molecules and counts of their predicted "active" and "inactive" docked poses as predicted by the three top MLs. figure 7A where the distance separating the electrophilic carbamate atom of 9 fosamprenavir and the nucleophilic Ser478 OH never crossed the threshold magenta 10 line. Accordingly, we were prompted to discard fosamprenavir from subsequent 11 covalent docking. However, the other two hits (capreomycin and aspoxicillin) remained 12 during MD simulation within the active site ( Figure 7A ). However, aspoxicillin seems 13 to have better chances to form covalent bond with Ser478 as it crosses/approaches the (Figures 8C and 8D) . Moreover, covalent docking shows that each docked (Figures 8A and 8B) . Similarly, docked 24 capreomycin is involved in hydrogen bonding interactions with Gln475, His333, 1 Ser497, Gly476, His316, and Gly428. Additionally, the guanidine of capereomycin is 2 stacked against the imidazole side chain of His333. 3 Covalent docking, however, is only a decorative tool to suggest how a covalent-bond 4 forming drug might fit into the binding pocket in case it succeeds in forming covalent 5 bond. However, we believe the main supportive tool in our case is MD simulations. To 6 enhance confidence in MD simulations as success gauge for our ML models, we 7 performed MD simulations (200 ns) for further 4 compounds (starting with high-quality 8 docked poses of consensus score of 9), namely, camostat (2), cobicistat (33), ibrutinib 9 (206) and piritrexim (242) . The former two belong to the testing set, while the latter 10 two belong to the screened set. Camostat is the only active compound among the 11 collection and it was correctly predicted by our ML models to be active. While the other 12 three were all predicted to be inactive by our models, however one of them, i.e., 13 cobicistat, is experimentally proven to be inactive. This collection should allow us to 14 adequately probe the correlation between our ML predictions and MD simulation data. 15 Figure 7B shows the results of the MD study. Clearly, only camostat persisted within 16 the vicinity of the binding site, while the rest, whether experimentally inactive or 17 predicted to be inactive, were quickly ejected from the binding site. These results nicely 18 correlate with the predictions of our ML models despite being generated for rather 19 diverse set of compounds. In the present work we introduce computational bootstrapping of machine learning 3 QSAR modelling using multiple high-quality docked poses. Ligand-receptor contact 4 fingerprints and scoring function values were used as descriptors, while several MLs 5 were scanned. We implemented this method for the discovery of potential inhibitors for 6 the serine protease enzyme TMPRSS2 involved in the infectivity of coronaviruses. 7 Three hits were identified. Subsequent molecular dynamic simulation and covalent 8 docking supported the results of the new computational approach. Recent advances in computer-aided drug design Binding Affinity via Docking: Fact and Fiction Efficient drug lead discovery and optimization. Accounts of chemical 27 research Molecular Docking: Shifting Paradigms in Drug Discovery Task-Specific Scoring Functions for Predicting 2 Ligand Binding Poses and Affinity and for Screening Enrichment QM/MM and molecular dynamics investigation of 5 the mechanism of covalent inhibition of TAK1 kinase Protein-Based Virtual Screening of Chemical 8 Databases. 1. Evaluation of Different Docking/Scoring Combinations High-Throughput Docking Using Quantum Mechanical 11 Scoring Virtual 13 Screening with AutoDock: Theory and Practice Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-21 Knowledge-based scoring function to predict 24 protein-ligand interactions LigScore: a 2 novel scoring function for predicting binding affinities Flexi-pharma: a molecule-5 ranking strategy for virtual screening using pharmacophores from ligand-free 6 conformational ensembles An Overview of Scoring Functions Used for Protein-Ligand 9 Molecular Docking. Interdisciplinary Sciences: Computational Life 10 Sciences Prediction of ligand binding mode among multiple cross-docking 12 poses by molecular dynamics simulations Prediction of protein-ligand binding affinity by free energy 15 simulations: assumptions, pitfalls and expectations A knowledge-based scoring function for protein-ligand interactions: 18 Probing the reference state. Virtual Screening: An Alternative or Complement to 19 High Throughput Screening? Effect of ligand volume correction on PMF scoring PMF Scoring Revisited A General and Fast Scoring Function for Protein−Ligand 25 Interactions: A Simplified Potential Approach Validation Studies of the Site-Directed 2 A Fast Flexible Docking Method using 5 an Incremental Construction Algorithm Molecular dynamics analysis to 8 evaluate docking pose prediction Advances in Docking. Current Medicinal 10 Chemistry SCORE: A New Empirical Method for Estimating 12 the Binding Affinity of a Protein-Ligand Complex Prediction of binding constants of protein ligands: a fast method for the 15 prioritization of hits obtained from de novo design or 3D database search programs Ranking poses in structure-based lead discovery and 18 optimization: current trends in scoring function development FlexX suite. Chem World-Uk Prediction of Protein−Ligand Interactions. 22 Docking and Scoring: Successes and Gaps Impact of Scoring Functions on Enrichment in Docking-25 Based Virtual Screening: An Application Study on Renin Inhibitors † Virtual ligand screening: strategies, perspectives and limitations. Drug 28 discovery today Crystal contacts as nature's docking solutions Comparative Intermolecular Contacts Analysis as New 3-D QSAR Concept for Validating Docking Studies and in Silico Screening: NMT and GP Inhibitors as Case Combining docking-based 6 comparative intermolecular contacts analysis and k-nearest neighbor correlation for 7 the discovery of new check point kinase 1 inhibitors The use of docking-based comparative 10 intermolecular contacts analysis to identify optimal docking conditions within 11 glucokinase and to discover of new GK activators Application of docking-based comparative intermolecular 14 contacts analysis to validate Hsp90α docking studies and subsequent in silico 15 screening for inhibitors Combining molecular dynamics simulation and 17 ligand-receptor contacts analysis as a new approach for pharmacophore modeling: 18 beta-secretase 1 and check point kinase 1 as case studies Simulated annealing molecular dynamics and ligand-21 receptor contacts analysis for pharmacophore modeling Combining Stochastic Deformation/Relaxation and 24 Intermolecular Contacts Analysis for Extracting Pharmacophores from Ligand-25 Does a more precise chemical description of 28 protein-ligand complexes lead to more accurate prediction of binding affinity? 29 Journal of chemical information and modeling Structural protein-ligand interaction fingerprints (SPLIF) for 2 structure-based virtual screening: method and benchmark study Structural Interaction Fingerprint (SIFt): A Novel 5 Method for Analyzing Three-Dimensional Protein−Ligand Binding Interactions Expanded Interaction Fingerprint Method for Analyzing 8 Ligand Binding Modes in Docking and Structure-Based Drug Design 11 Interacting with GPCRs: Using Interaction Fingerprints for Virtual Screening Knowledge-Based Interaction 14 Fingerprint Scoring: A Simple Method for Improving the Effectiveness of Fast 15 Scoring Functions APIF: A New Interaction 18 Fingerprint Based on Atom Pairs and Its Application to Virtual Screening Optimizing Fragment and Scaffold Docking by Use of 21 Molecular Interaction Fingerprints Life beyond the Tanimoto coefficient: similarity 24 measures for interaction fingerprints Discovery of Subtype Selective Janus Kinase 26 (JAK) Inhibitors by Structure-Based Virtual Screening Model-based machine learning Artificial intelligence for decision making in the 2 era of Big Data -evolution, challenges and research agenda Deep learning in drug discovery: opportunities, challenges and future 5 prospects Deep Learning in Medical 7 Imaging: General Overview Pangenome-reverse vaccinology approach for identifications of potential vaccine 10 candidates in microbial pangenome Vaxign-ML: 12 supervised machine learning reverse vaccinology model for improved prediction of 13 bacterial protective antigens Applications of machine learning in drug discovery and development Artificial intelligence in drug 18 design Deep learning and virtual drug 20 screening Naive Bayes: applications, variations and 2 vulnerabilities: a review of literature with code snippets for implementation A Novel Image Classification Method with CNN-5 Smart Grid Environment. Computational Intelligence 9 for Multimedia Big Data on the Cloud with Engineering Applications A comparative 12 study on various data mining classification methods: KNN, PNN and ANN for tiles 13 defect detection Support vector machines for drug discovery Ligand based virtual screening using SVM on GPU A probabilistic neural network approach for modeling and 21 classification of bacterial growth/no-growth data Diagnosing Breast Cancer Type by Using Probabilistic 24 Neural Network in Decision Support System Application of probabilistic 27 neural networks in modelling structural deterioration of stormwater pipes Applications of Data Mining in the Healthcare Industry. 30 Encyclopedia of Healthcare Information Systems Data mining applications in healthcare Advanced methods in neural computing Neural Networks for Identification of Nonlinear Systems: An 6 Recurrent neural network prediction of steam production in a 8 Bootstrapping the out-of-sample 11 predictions for efficient and accurate cross-validation Classifier performance estimation under the 14 constraint of a finite sample size: resampling schemes applied to neural network 15 classifiers Making do with what we have: use your 17 bootstraps From SARS to MERS: 10 years of research on highly 19 pathogenic human coronaviruses SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 22 Clinically Proven Protease Inhibitor Targeting Novel 24 Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising 25 Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase Airway proteases: an emerging drug target for influenza and 28 other respiratory virus infections Potential clinical drugs as covalent inhibitors of the 2 priming proteases of the spike protein of SARS-CoV-2 Identification of the first synthetic inhibitors of the type II 6 transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus 7 activation PolypharmDB, a deep learning-based resource, quickly identifies repurposed drug 10 candidates for COVID-19 Homology Modeling 12 of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into 13 Human Cells Gene of the month: TMPRSS2 (transmembrane serine 15 protease 2) Coronavirus Cases Potential 18 Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming Recent progress on inhibitors of the type II 21 transmembrane serine proteases, hepsin, matriptase and matriptase-2. Future 22 Medicinal Chemistry 24 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory 25 Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-26 Protein-Based Cell-Cell Fusion Assay Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for 31 COVID-19 The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: 3 an existing drug with multiple possible therapeutic effects. Cold Spring Harbor 4 Laboratory 101. ClinicalTrials.gov. Identifier NCT04352400, Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA) 102. ClinicalTrials.gov. Identifier NCT04470544, CamostatMesilate Treating Patients 8 With Hospitalized Patients With COVID-19 (RECOVER). In: (US) BMNLoM Targeted Covalent Inhibitors for Drug Design Serine proteases: how did chemists tease out their catalytic 13 mechanism? Drug discovery for a new generation of covalent drugs Impact of the structures of macrocyclic Michael 19 acceptors on covalent proteasome inhibition A road 21 map to evaluate the proteome-wide selectivity of covalent kinase inhibitors Chemical Probes that Target Serine Hydrolases Carbamates with Differential Mechanism of Inhibition Toward Acetylcholinesterase 27 and Butyrylcholinesterase Organic carbamates in drug design and medicinal chemistry The pharmacological landscape and therapeutic 2 potential of serine hydrolases Targeting biomolecules with reversible covalent 4 chemistry A 6 comparative study of the binding properties linagliptin, saxagliptin, sitagliptin and vildagliptin in mice A 11 comparative study of the binding modes of recently launched dipeptidyl peptidase IV 12 inhibitors in the active site Advances 15 in covalent kinase inhibitors Synthetic 17 and structural studies on syringolin A and B reveal critical determinants of 18 selectivity and potency of proteasome inhibition A 21 plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel 22 mechanism The oxa-Michael reaction: from recent developments to 24 applications in natural product synthesis Microwave-Assisted Metal-Free Decarboxylative 27 Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and 1 potential antiglaucoma agents Synthesis and binding 4 affinity of new muscarinic ligands structurally related to oxotremorine Trisubstituted Isoxazoles from Morita-Baylis-Hillman Acetates by an NaNO2 Mediated Domino Reaction Synthesis and biological activity of furoxan derivatives against Mycobacterium 11 tuberculosis Emerging and Re-Emerging Warheads for Targeted 13 Synthesis, structural characterization and cytotoxic activity of heterocyclic 17 compounds containing the furoxan ring Nitro-Group-Containing Drugs The Nitro Group as a Masked 23 Electrophile in Covalent Enzyme Inhibition New Electrophiles and Strategies for Mechanism-Based and 25 Studies on furan 27 derivatives.XIV. Nucleophilic substitution of methyl 5-nitro-2-furancarboxylate and 28 5-Nitrofuran-2-nitrile A new general synthesis of functionally 2 substituted pyrazolo[1,5-a]pyrimidines Mechanistic insights into a classic wonder drug--5 aspirin Structure 7 of human prostasin, a target for the regulation of hypertension Active site conformational changes of prostasin provide a new mechanism of 11 protease regulation by divalent cations Synthesis and structure-activity 13 relationships of small-molecular di-basic esters, amides and carbamates as flaviviral 14 protease inhibitors The 16 Structure of the Extracellular Region of Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 21 with camostat and nafamostat The Kinetic and Structural 23 Characterization of the Reaction of Nafamostat with Bovine Pancreatic Trypsin Serine protease Hepsin in complex with Inhibitor. Worldwide Protein Data Bank 29 BLAST+: architecture and applications HHblits: lightning-fast iterative protein 31 sequence searching by HMM-HMM alignment SWISS-MODEL: homology modelling of protein structures and complexes Automated comparative protein structure 5 modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective More and better reference data for improved all-atom structure 9 validation Structure validation by Cα geometry: ϕ,ψ and Cβ deviation High throughput docking for library design and library 14 prioritization LigandFit: a novel method 16 for the shape-directed rapid docking of ligands to protein active sites Detailed analysis of grid-based 19 molecular docking: A case study of CDOCKER?A CHARMm-based MD docking 20 algorithm Detailed analysis of grid-based 22 molecular docking: A case study of CDOCKER-A CHARMm-based MD docking 23 algorithm Structure Prediction: Covalent Inhibitors of Serine Proteases and Design of Site-26 Directed Combinatorial Libraries A general and fast scoring function for protein-ligand 28 interactions: a simplified potential approach A knowledge-based scoring function for protein-ligand interactions: 2 Probing the reference state. Virtual Screening: An Alternative or Complement to Consensus scoring for 5 ligand/protein interactions Consensus scoring for protein-ligand interactions The 10 SWISS-MODEL Repository-new features and functionality QMEANDisCo-distance constraints applied on model quality estimation Modeling protein quaternary 16 structure of homo-and hetero-oligomers beyond binary interactions by homology Bioactive Molecule Prediction Using Extreme 19 Gradient Boosting. Molecules Distance 21 and similarity measures effect on the performance of k-nearest neighbor classifier-a 22 review Probabilistic neural network for evaluating seismic liquefaction potential Tumor classification by 26 combining PNN classifier ensemble with neighborhood rough set based gene 27 reduction Development of novel 29 in silico prediction model for drug-induced ototoxicity by using naive Bayes 30 classifier approach Support vector machines for drug discovery Virtual screening 14 workflow development guided by the "receiver operating characteristic" curve 15 approach. Application to high-throughput docking on metabotropic glutamate 16 receptor subtype 4 Evaluation of the 18 performance of 3D virtual screening protocols: RMSD comparisons, enrichment 19 assessments, and decoy selection--what can we learn from earlier mistakes Pharmacophore 22 features for machine learning in pharmaceutical virtual screening Interrater reliability: the kappa statistic Applications of machine learning techniques 28 to predict filariasis using socio-economic factors Practical Bayesian model evaluation using 2 leave-one-out cross-validation and WAIC Docking 5 covalent inhibitors: a parameter free approach to pose prediction and scoring The measurement of observer agreement for categorical data Molecular dynamics 10 simulations of the interaction of Mouse and Torpedo acetylcholinesterase with 11 covalent inhibitors explain their differential reactivity: Implications for drug 12 design QM/MM and molecular dynamics 14 investigation of the mechanism of covalent inhibition of TAK1 kinase 4D-quantitative structure-activity relationship modeling: 17 making a comeback GAMBLE: a tool for fast and facile 19 generation of random data for statistical evaluation of QSAR models Applicability Domain: A Step Toward Confident 22 Predictions and Decidability for QSAR Modeling Molecular Docking Programs for Virtual Screening against Dihydropteroate 26 Effects of Variable Docking Conditions and Scoring 28 Functions on Corresponding Protein-Aligned Comparative Molecular Field Analysis 29 Models Constructed from Diverse Human Protein Tyrosine Phosphatase 1B Software for molecular docking: a review Mutasem Taha: Conceptualization, Methodology, Supervision, Resources, Formal 6 analysis, Investigation, Writing -review & editing. Ma'mon M. Hatmal: Formal 7 analysis, Investigation, Resources, Writing -original draft, review & editing. Omar 8 Abuyman: Investigation, Resources, Review & Editing